The aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000UI/0.25 mL - HIPOLABOR) in relation to the drug compared (heparin sodium 5.000USP/mL - APP) in preventing the development of venous thromboembolism (VTE) in patients undergoing surgery for medium risk for the development of this pathology.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
140
5.000 UI/0,25mL
5.000 USP/mL
Lal Clinica Pesquisa E Desenvolvimento Ltda
Valinhos, São Paulo, Brazil
Non-appearance of venous thromboembolism
Time frame: 2 h before the start of surgery, 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.